News & Videos - BIOLINERX LTD. ADS

You are currently viewing all stock exchange news of the financial instrument BIOLINERX LTD. ADS regarding all markets in all languages.

> News PR Newswire published a news.

BioLineRx Announces Poster Presentation on Apheresis Center Efficiency and CXCR4 Antagonists including APHEXDA® (motixafortide) in Patients with Multiple Myeloma at the ASFA 2024 Annual Meeting PR Newswire TEL AVIV, Israel, April 17, 2024 TEL AVIV, Israel , April 17, 2024 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced a poster presentation on apheresis center...

Thank you Chart

> News PR Newswire published a news.

BioLineRx Accesses Second Tranche of $20 Million Under Previously Announced $40 Million Non-Dilutive Debt Financing Agreement • • PR Newswire • Stocks

BioLineRx Accesses Second Tranche of $20 Million Under Previously Announced $40 Million Non-Dilutive Debt Financing Agreement PR Newswire TEL AVIV, Israel, April 10, 2024 - Proceeds to be used to further accelerate uptake of APHEXDA® in stem cell mobilization, life-cycle expansion activities in sickle cell disease, and motixafortide metastatic pancreatic cancer program - TEL AVIV, Israel , April 10, 2024 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ/TASE: BLRX), a commercial stage biopharmaceutical...

Thank you Chart

> News PR Newswire published a news.

BioLineRx Announces $6 Million Registered Direct Offering • • PR Newswire • Stocks

BioLineRx Announces $6 Million Registered Direct Offering PR Newswire TEL AVIV, Israel, April 1, 2024 TEL AVIV, Israel , April 1, 2024 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX) ("BioLineRx" or the "Company"), a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced that it has entered into definitive agreements with several institutional investors for the issuance and sale in a registered direct offering of...

Thank you Chart

> News PR Newswire published a news.

BioLineRx Reports 2023 Financial Results and Recent Corporate and Portfolio Updates • • PR Newswire • Stocks

BioLineRx Reports 2023 Financial Results and Recent Corporate and Portfolio Updates PR Newswire TEL AVIV, Israel, March 26, 2024 - Reported significant commercial progress for APHEXDA® -- secured payer coverage representing ~95% of covered lives in the U.S.; continued progress on formulary approvals at targeted major transplant centers; r eceived Healthcare Common Procedure Coding System (HCPCS) J-Code to facilitate Medicare reimbursement - - Announced first patient dosed in randomized Phase 2b...

Thank you Chart

> News PR Newswire published a news.

BioLineRx to Report 2023 Annual Financial Results on March 26, 2024 • • PR Newswire • Stocks

BioLineRx to Report 2023 Annual Financial Results on March 26, 2024 PR Newswire TEL AVIV, Israel, March 20, 2024 - Management to Hold Conference Call at 08:30 a.m. EDT - TEL AVIV, Israel , March 20, 2024 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced it will release its audited financial results for the year ended December 31, 2023 on Tuesday, March 26, 2024 ,...

Thank you Chart

> News PR Newswire published a news.

BioLineRx Strengthens Intellectual Property Estate with Notice of Allowance for U.S. Patent Covering Method of Manufacturing Motixafortide (BL-8040) Suitable for Large Scale Production PR Newswire TEL AVIV, Israel, March 4, 2024 - New patent, when issued, will be valid until December 2041 - - Additional IP complements U.S. market exclusivity awarded to BioLineRx upon FDA approval of APHEXDA® (motixafortide) in September 2023 as a result of its Orphan Drug and New Chemical Entity designations -...

Thank you Chart

> News PR Newswire published a news.

BioLineRx Announces First Patient Dosed in Randomized Phase 2 Combination Clinical Trial Evaluating Motixafortide in First-Line Pancreatic Cancer (PDAC) • • PR Newswire • Stocks

BioLineRx Announces First Patient Dosed in Randomized Phase 2 Combination Clinical Trial Evaluating Motixafortide in First-Line Pancreatic Cancer (PDAC) PR Newswire TEL AVIV, Israel, Feb. 28, 2024 - Conducted in Collaboration with Columbia University , the CheMo4METPANC Phase 2 trial is the first large, multi-center, randomized study evaluating motixafortide with a PD-1 inhibitor and first-line PDAC chemotherapies compared to chemo alone - - Gulam Manji , MD, PhD, of Columbia University to...

Thank you Chart

> News PR Newswire published a news.

BioLineRx Announces Acceptance of Two Poster Presentations on APHEXDA® (motixafortide) for CD34+ Hematopoietic Stem Cell (HSC) Mobilization in Patients with Multiple Myeloma at the 2024 Tandem Meetings of ASTCT® and CIBMTR® PR Newswire TEL AVIV, Israel, Feb. 16, 2024 Results include pharmacokinetic and pharmacodynamic data, and post-hoc subgroup analyses of the Phase 3 GENESIS trial Presentations on Thursday, February 22, 2024 in San Antonio, Texas TEL AVIV, Israel , Feb. 16, 2024...

Thank you Chart

> News PR Newswire published a news.

BioLineRx Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating Motixafortide for CD34+ Hematopoietic Stem Cell Mobilization for Gene Therapies in Sickle Cell Disease PR Newswire TEL AVIV, Israel, Dec. 21, 2023 - Proof-of-concept study is initial step toward goal of identifying more efficient CD34+ HSC mobilization regimen for patients with sickle cell disease choosing gene therapy - TEL AVIV, Israel , Dec. 21, 2023 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a...

Thank you Chart

> News PR Newswire published a news.

BioLineRx Reports Third Quarter 2023 Financial Results and Recent Corporate and Portfolio Updates • • PR Newswire • Stocks

BioLineRx Reports Third Quarter 2023 Financial Results and Recent Corporate and Portfolio Updates PR Newswire TEL AVIV, Israel, Nov. 20, 2023 - Received FDA Approval of APHEXDA® (motixafortide) in Combination with Filgrastim (G-CSF) to Mobilize Hematopoietic Stem Cells for Collection and Subsequent Autologous Transplantation in Patients with Multiple Myeloma - - Closed Exclusive License Agreement for Motixafortide in Asia Region with Concurrent Strategic Equity Investment - - Presented...

Thank you Chart

> News PR Newswire published a news.

BioLineRx to Report Third Quarter 2023 Results on November 20, 2023 • • PR Newswire • Stocks

BioLineRx to Report Third Quarter 2023 Results on November 20, 2023 PR Newswire TEL AVIV, Israel, Nov. 13, 2023 - Management to Hold Conference Call at 10:00 a.m. EST - TEL AVIV, Israel , Nov. 13, 2023 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced it will release its unaudited financial results for the quarter ended September 30, 2023 on Monday, November 20,...

Thank you Chart

> News PR Newswire published a news.

BioLineRx a conclu un accord de licence exclusive concernant le motixafortide en Asie, sur les conseils de MSQ Ventures • • PR Newswire • Stocks

BioLineRx a conclu un accord de licence exclusive concernant le motixafortide en Asie, sur les conseils de MSQ Ventures PR Newswire NEW YORK, 1er novembre 2023 NEW YORK , 1er novembre 2023 /PRNewswire/ -- MSQ Ventures (« MSQ ») a le plaisir d'annoncer que son client, BioLineRx Ltd. (« BioLineRx ») (NASDAQ/TASE: BLRX), a conclu un accord de licence exclusive avec Guangzhou Gloria Biosciences Co., Ltd. (« GloriaBio ») et un investisseur associé pour le développement, en Asie, du...

Thank you Chart

> News PR Newswire published a news.

BioLineRx celebró un acuerdo de licencia exclusivo para Motixafortide en Asia, asesorado por MSQ Ventures • • PR Newswire • Stocks

BioLineRx celebró un acuerdo de licencia exclusivo para Motixafortide en Asia, asesorado por MSQ Ventures PR Newswire NUEVA YORK, 31 de octubre de 2023 NUEVA YORK , 31 de octubre de 2023 /PRNewswire/ -- MSQ Ventures ("MSQ") se complace en anunciar que su cliente, BioLineRx Ltd. ("BioLineRx") (NASDAQ/TASE: BLRX), ha celebrado un acuerdo de licencia exclusivo con Guangzhou Gloria Biosciences Co., Ltd. (GloriaBio) y un inversor asociado para el desarrollo de motixafortida en todas las indicaciones...

Thank you Chart

> News PR Newswire published a news.

BioLineRx schließt exklusive Lizenzvereinbarung für Motixafortide in Asien, beraten von M.S.Q. Ventures • • PR Newswire • Stocks

BioLineRx schließt exklusive Lizenzvereinbarung für Motixafortide in Asien, beraten von M.S.Q. Ventures PR Newswire NEW YORK, 31. Oktober 2023 NEW YORK , 31. Oktober 2023 /PRNewswire/ -- M.S.Q. Ventures („MSQ") freut sich bekanntgeben zu können, dass sein Kunde BioLineRx Ltd. („BioLineRx") (NASDAQ/TASE: BLRX) eine exklusive Lizenzvereinbarung mit Guangzhou Gloria Biosciences Co., Ltd. („GloriaBio") und einem assoziierten Investor für die Entwicklung von Motixafortide für alle...

Thank you Chart

> News PR Newswire published a news.

BioLineRx firmó un acuerdo de licencia exclusiva para Motixafortide en Asia, con el asesoramiento de M.S.Q. Emprendimientos • • PR Newswire • Stocks

BioLineRx firmó un acuerdo de licencia exclusiva para Motixafortide en Asia, con el asesoramiento de M.S.Q. Emprendimientos PR Newswire NUEVA YORK, 31 de octubre de 2023 NUEVA YORK , 31 de octubre de 2023 /PRNewswire/ -- M.S.Q. Ventures ("MSQ") se complace en anunciar que su cliente, BioLineRx Ltd. ("BioLineRx") (NASDAQ/TASE: BLRX), ha celebrado un acuerdo de licencia exclusiva con Guangzhou Gloria Biosciences Co., Ltd. (GloriaBio) y un inversionista asociado, para el desarrollo de...

Thank you Chart

> News PR Newswire published a news.

BioLineRx entered Exclusive License Agreement to Motixafortide in Asia, advisored by M.S.Q. Ventures • • PR Newswire • Stocks

BioLineRx entered Exclusive License Agreement to Motixafortide in Asia, advisored by M.S.Q. Ventures PR Newswire NEW YORK, Oct. 31, 2023 NEW YORK , Oct. 31, 2023 /PRNewswire/ -- M.S.Q. Ventures ("MSQ") is pleased to announce that its client, BioLineRx Ltd. ("BioLineRx") (NASDAQ/TASE: BLRX), has entered into an exclusive license agreement with Guangzhou Gloria Biosciences Co., Ltd. (GloriaBio) and an associated investor for the development of motixafortide across all indications in Asia. The...

Thank you Chart

> News PR Newswire published a news.

BioLineRx entered Exclusive License Agreement to Motixafortide in Asia, advisored by M.S.Q. Ventures • • PR Newswire • Stocks

Thank you Chart

> News PR Newswire published a news.

BioLineRx entered Exclusive License Agreement to Motixafortide in Asia, advisored by M.S.Q. Ventures • • PR Newswire • Stocks

Thank you Chart

> News PR Newswire published a news.

BioLineRx Announces Closing of Exclusive License Agreement to Motixafortide in Asia and Concurrent Strategic Equity Investment • • PR Newswire • Stocks

BioLineRx Announces Closing of Exclusive License Agreement to Motixafortide in Asia and Concurrent Strategic Equity Investment PR Newswire TEL AVIV, Israel, Oct. 12, 2023 - License agreement includes $15 million upfront, up to $50 million in potential development and regulatory milestones; up to ~$200 million in potential commercial milestones, and tiered double-digit royalties on sales - - Gloria Biosciences expected to begin bridging study to support potential approval and commercialization of...

Thank you Chart

> News PR Newswire published a news.

BioLineRx Announces Encouraging Data from Pilot Phase of Phase 2 Combination Clinical Trial with Motixafortide in First-Line Pancreatic Cancer (PDAC) • • PR Newswire • Stocks

BioLineRx Announces Encouraging Data from Pilot Phase of Phase 2 Combination Clinical Trial with Motixafortide in First-Line Pancreatic Cancer (PDAC) PR Newswire TEL AVIV, Israel, Sept. 28, 2023 - 6 of 11 Patients in the Pilot Phase Experienced a Partial Response, with 4 Confirmed; One Patient Experienced Resolution of the Hepatic Metastatic Lesion - - Data Presented at AACR Special Conference on Pancreatic Cancer - - Multi-Center, Randomized Phase 2 Study Currently Enrolling - TEL AVIV, Israel...

Thank you Chart